Hepatitis C and insulin resistance: Mutual interactions. A review

Acta Clinica Belgica

Volumn 62, Issue 2, 2007, Pages 111-119

  Decock, S ^a   Verslype, C ^a   Fevery, J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Diabetes; HCV core protein; Hepatitis C; Insulin resistance; Steatosis

Indexed keywords

ADIPONECTIN; CORE PROTEIN; GLUCOSE TRANSPORTER 4; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

DISEASE COURSE; DISEASE PREDISPOSITION; FATTY LIVER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; LIVER CIRRHOSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PREVALENCE; REVIEW;

EID: 34248188017     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2007.019     Document Type: Review

References (60)

1. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006; 40 (Suppl 1):S17-29.
2. Farrell GC, Larter CZ. Nonalcoholic Fatty Liver Disease: from Steatosis to Cirrhosis. Hepatology 2006; 43: S 99-S 112.
3. Wilcox G. Insulin and Insulin Resistance. Clin Biochem Rev 2005; 26 (2):19-39.
4. Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and Insulin Resistance: Insuline Hypersecretion and Specific Association with the Insulin Resistance Syndrome. Hepatology 2002; 35: 373-9.
5. Pagano G, Pacini G, Musso G et al. Nonalcoholic Steatohepatitis, Insulin Resistance, and Metabolic Syndrome: Further Evidence for an Etiologic Association. Hepatology 2002; 35: 367-72.
6. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome. Hepatology 2003; 37: 917-23.
7. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002; 37: 56-62.
8. Ruhl CE, Everhart JE. Determinants of the Association of Overweight with Elevated Serum Alanine Aminotransferase Activity in the United States. Gastroenterology 2003; 124: 71-9.
9. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985; 28: 412-9.
10. Bonora E, Targher G, Alberiche M et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care 2000; 23: 57-63.
11. Katz A, Nambi SS, Mather K et al. Quantitative insulin-sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-10.
12. Trayhurn P. Endocrine and signalling role of adipose tissue: new perspectives on fat. Acta Physiol Scand 2005; 184: 285-93.
13. Vettor R, Milan G, Rossato M, Federspil G. Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther 2005; 22 Suppl 2: 3-10.
14. Nedvidkova J, Smitka K, Kopsky V, Hainer V. Adiponectin, an adipocyte-derived protein. Physiol Res 2005;54(2):133-40.
15. You T, Yang R, Lyles MF, Gong D, Nicklas BJ. Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors. Am J Physiol Endocrinol Metab 2005; 288: E741-E7.
16. Lutchman G, Promrat K, Kleiner DE et al. Changes in Serum Adipokine Levels During Pioglitazone Treatment for Nonalcoholic Steatohepatitis: Relationship to Histological Improvement. Clin Gastroenterol Hepatol 2006; 4: 1048-52.
17. Musso G, Gambino R, Biroli G et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2005; 100: 2438-46.
18. Korner J, Leibel RL. To eat or not to eat - how the gut talks to the brain. N Engl J Med 2003; 349: 926-8.
19. Kaplan LM. Leptin, obesity, and liver disease. Gastroenterology 1998; 115: 997-1001.
20. Marra F. Leptin and liver fibrosis: a matter of fat. Gastroenterology 2002; 122: 1529-32.
21. Chalasani N, Crabb DW, Cummings OW et al. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol 2003; 98: 2771-6.
22. Dubuquoy L, Dharacy S, Nutten S, Pettersson S, Auwerx J, Desreumax P. Role of peroxisome proliferator-activated receptora and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet 2002; 360: 1410-8.
23. Yeon J, Choi K, Baik S et al. Reduced expression of peroxisome proliferator-activated receptor-α may have an important role in the development of non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2004; 19: 799-804.
24. Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumenliver interactions and possible role for probiotics. J Hepatol 2003; 38: 681-7.
25. Sreekumar R, Rosado B, Rasmussen D, Charlton M. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 2003; 38: 244-51.
26. Damcott CM, Moffett SP, Feingold E et al. Genetic variation in Fatty Acid-Binding Protein-4 and Peroxisome Proliferator-Activated Receptor γ interactively influence insulin sensitivity and body composition in males. Metabolism 2004; 53: 303-9.
27. Kruszynska Y, Home P, McIntyre N. Relationship between insulin sensitivity, insulin secretion and glucose tolerance in cirrhosis. Hepatology 1991;14:103-11.
28. Petrides AS, Stanley T, Matthews D, Vogt C, Bush A, Lambeth H. Insulin resistance in cirrhosis: prolonged reduction of hyperinsulinemia normalizes insulin sensitivity. Hepatology 1998;28:141-9.
29. Caronia S, Taylor K, Pagliaro L et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999;30:1059-63.
30. Petit JM, Bour JB, Galland-Jos C, Minello A et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001; 35: :279-83.
31. Sougleri M, Labropoulou-Karatza C, Paraskevopoulou P, Fragopanagou H, Alexandrides T. Chronic hepatitis C virus infection without cirrhosis induces insulin resistance in patients with alpha-thalassaemia major. Eur J Gastroenterol Hepatol 2001; 13: 1195-9.
32. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol 2001; 96: 2462-7.
33. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-9.
34. Mason AL, Lau JY, Hoang N et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999;29:328-33.
35. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
36. Chang KM. Immunopathogenensis of hepatitis C virus infection. Clin Liver Dis 2003; 7: 89-105.
37. Rubbia-Brandt L, Quadri R, Abid K et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000;33:106-15.
38. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. .Hepatology 2001;33: 1358-64.
39. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005; 100: 1509-15.
40. Wu JY, Chen SL, Qiang GW. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C. Liver Int 2006; 26: 166-72.
41. Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T, LIDO Study Group. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003; 39: 1049-55.
42. Hickman IJ, Powell EE, Prins JB et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003; 39: 1042-8.
43. Marra F. Leptin and liver fibrosis: a matter of fat. Gastroenterology 2002; 122: 1529-32.
44. Shepherd PR, Kahn BB. Glucose transporters and insulin action. N Engl J Med 1999;341:248-57.
45. Saltiel AR. Putting the brakes on insulin signaling. N Engl J Med 2003; 349: 2560-2.
46. Shintani Y, Fujie H, Miyoshi H et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-8.
47. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
48. Knobler H, Schattner A. TNF-{alpha}, chronic hepatitis C and diabetes: a novel triad. Review. QJM 2005; 98:1-6.
49. Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 2003; 14: 447-55.
50. Valenti L, Pulixi E, Fracanzani AL et al. TNFalpha genotype affects TNF alpha release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis. J Hepatol 2005; 43: 944-50.
51. Aetug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signalling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 2003;38:1384-92.
52. Moriya K, Yotsuyanagi H, Shintani Y et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997;78:1527-53.
53. Perlemuter G, Sabile A., Letteron P et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion : a model of viral related steatosis. FASEB J 2002;16: 185-94.
54. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002;36:1266-72.
55. Kim JK, Fillmore JJ, Chen Y et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci USA 2001; 98: 7522-7.
56. Yamaguchi A, Tazuma S, Nishioka T et al. Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver. Dig Dis Sci 2005; 50: 1361-71.
57. Walsh MJ, Jonsson JR, Richardson MM et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55: 529-35.
58. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez M. Insulin resistance impairs sustained response rate to Peginterferon plus Ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.
59. Zierath JR. Exercise training-induced changes in insulin signaling in skeletal muscle. J Appl Physiol 2002; 93: 773-81.
60. Caldwell SH, Argo CK, Al-Osaimi AMS. Therapy of NAFLD: Insulin Sensitizing Agents. J Clin Gastroenterol 2006; 40: S61-S6.